Nano-enhanced immunity: A bibliometric analysis of nanoparticles in vaccine adjuvant research.

IF 4.1 4区医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-11-14 DOI:10.1080/21645515.2024.2427464

Manal Mohamed Elhassan Taha, Siddig Ibrahim Abdelwahab, Sivakumar S Moni, Abdullah Farasani, Ieman A Aljahdali, Bassem Oraibi, Hassan Ahmad Alfaifi, Amal Hamdan Alzahrani, Ahmed Ali Jerah

{"title":"Nano-enhanced immunity: A bibliometric analysis of nanoparticles in vaccine adjuvant research.","authors":"Manal Mohamed Elhassan Taha, Siddig Ibrahim Abdelwahab, Sivakumar S Moni, Abdullah Farasani, Ieman A Aljahdali, Bassem Oraibi, Hassan Ahmad Alfaifi, Amal Hamdan Alzahrani, Ahmed Ali Jerah","doi":"10.1080/21645515.2024.2427464","DOIUrl":null,"url":null,"abstract":"<p><p>This study analyzed the growth, collaboration, citation trends, and emerging topics in nanoparticle-based vaccine and adjuvant research (NVAR) from 1977 to 2023, using data from the Scopus database. The field showed a steady growth rate of 7.53% per year. Leading researchers Jaafari, M.R. and Alving, C.R. contributed significantly to the field, with 24.22% of publications and 38.92% of total citations coming from the United States. International collaboration was very strong, particularly between the US, UK, Germany, China, and France. Key research topics include nanoparticles, immunotherapy, COVID-19, and vaccines with a focus on SARS-CoV-2 and malaria. Emerging topics include vaccine adjuvants, mRNA, and neutralizing antibodies. This study emphasizes the importance of ongoing collaboration and interdisciplinary efforts to advance the field of NVAR.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"20 1","pages":"2427464"},"PeriodicalIF":4.1000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11572201/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21645515.2024.2427464","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This study analyzed the growth, collaboration, citation trends, and emerging topics in nanoparticle-based vaccine and adjuvant research (NVAR) from 1977 to 2023, using data from the Scopus database. The field showed a steady growth rate of 7.53% per year. Leading researchers Jaafari, M.R. and Alving, C.R. contributed significantly to the field, with 24.22% of publications and 38.92% of total citations coming from the United States. International collaboration was very strong, particularly between the US, UK, Germany, China, and France. Key research topics include nanoparticles, immunotherapy, COVID-19, and vaccines with a focus on SARS-CoV-2 and malaria. Emerging topics include vaccine adjuvants, mRNA, and neutralizing antibodies. This study emphasizes the importance of ongoing collaboration and interdisciplinary efforts to advance the field of NVAR.

查看原文本刊更多论文

纳米增强免疫：疫苗佐剂研究中纳米粒子的文献计量分析。

本研究利用 Scopus 数据库中的数据，分析了 1977 年至 2023 年基于纳米粒子的疫苗和佐剂研究（NVAR）的增长、合作、引用趋势和新兴课题。该领域每年以 7.53% 的速度稳步增长。主要研究人员Jaafari, M.R.和Alving, C.R.为该领域做出了重大贡献，24.22%的论文和38.92%的总引用来自美国。国际合作非常活跃，尤其是美国、英国、德国、中国和法国之间的合作。主要研究课题包括纳米粒子、免疫疗法、COVID-19和疫苗，重点是SARS-CoV-2和疟疾。新兴课题包括疫苗佐剂、mRNA 和中和抗体。这项研究强调了持续合作和跨学科努力对于推动 NVAR 领域发展的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Vaccines & Immunotherapeutics BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY

CiteScore

7.90

自引率

8.30%

发文量

489

审稿时长

3-6 weeks

期刊介绍： (formerly Human Vaccines; issn 1554-8619) Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics. Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.